tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Noxopharm Achieves Milestone in Autoimmune Drug Development with HERACLES Trial Completion

Story Highlights
  • Noxopharm completed the final cohort in the HERACLES trial for SOF-SKN, confirming its safety.
  • The trial’s success enhances Noxopharm’s position in the growing autoimmune disease market.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Noxopharm Achieves Milestone in Autoimmune Drug Development with HERACLES Trial Completion

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Noxopharm Ltd. ( (AU:NOX) ) is now available.

Noxopharm Limited announced the successful completion of the fourth and final single-dose cohort in the HERACLES clinical trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. The trial, conducted in Australia, confirmed the safety and tolerability of SOF-SKN at its highest dose, marking a significant milestone in its development. This advancement positions Noxopharm to further explore SOF-SKN’s potential applications in treating autoimmune-related skin diseases and other conditions linked to immune system dysregulation. The global market for cutaneous lupus erythematosus, one of the target diseases, is valued at over US$3.3 billion and is expected to grow, highlighting the commercial potential of Noxopharm’s innovations.

More about Noxopharm Ltd.

Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary Sofra™ and Chroma™ technology platforms to create a pipeline of new drugs targeting inflammation, autoimmunity, mRNA drug enhancement, and oncology. Noxopharm collaborates with leading researchers to enhance its drug development capabilities.

Average Trading Volume: 297,365

Technical Sentiment Signal: Buy

Current Market Cap: A$30.68M

See more data about NOX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1